bioXXmed (HMSE:T5O) - Stock Price, News & Analysis

T5O Stock Overview

An investment company, invests in biotechnology or medical technology companies with equity or debt capital. More details

T5O fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Earnings have declined by 60.3% per year over past 5 years

Makes less than USD$1m in revenue (€5K)

Does not have a meaningful market cap (€1M)

bioXXmed AG Competitors

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€22.5m

4SC

DB:VSC

€48.2m

Heidelberg Pharma

XTRA:HPHA

€102.1m

Price History & Performance

Summary of all time highs, changes and price drops for bioXXmed
Historical stock prices
Current Share Price	€1.90
52 Week High	€2.50
52 Week Low	€1.90
Beta	0.58
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-24.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	T5O	DE Biotechs	DE Market
7D	n/a	-0.2%	0.8%
1Y	n/a	-16.9%	9.1%

Return vs Industry: Insufficient data to determine how T5O performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how T5O performed against the German Market.

Price Volatility

Is T5O's price volatile compared to industry and market?
T5O volatility
T5O Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: T5O's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine T5O's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	1	Mark-André Freyberg	cytotools.de

bioXXmed AG, an investment company, invests in biotechnology or medical technology companies with equity or debt capital. It engages in the development of products for the diagnosis, alleviation, or cure of diseases through investments. The company was formerly known as CytoTools AG and changed its name to bioXXmed AG in September 2022.

bioXXmed AG Fundamentals Summary

How do bioXXmed's earnings and revenue compare to its market cap?
T5O fundamental statistics
Market cap	€1.43m
Earnings (TTM)	-€21.00m
Revenue (TTM)	€4.99k

286.0x

P/S Ratio

-0.1x

P/E Ratio

Is T5O overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
T5O income statement (TTM)
Revenue	€4.99k
Cost of Revenue	€0
Gross Profit	€4.99k
Other Expenses	€21.01m
Earnings	-€21.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-40.88
Gross Margin	100.00%
Net Profit Margin	-420,594.45%
Debt/Equity Ratio	0%

How did T5O perform over the long term?

See historical performance and comparison